Julia Stevens, PharmD
Tumor-infiltrating lymphocytes (TILs) may extend survival in patients with treatment-resistant melanoma, experts noted during the Hematology/Oncology Pharmacy Association Annual Conference 2023, in Phoenix.
Some of the most encouraging recent data emerged from a phase 3 trial of TILs in patients with metastatic melanoma (N Engl J Med 2022;387:2113-2125), although awareness of the therapy’s potential dates to the 1980s (N Engl J Med 1988;319[25]:1676-1680), noted